The new European guidelines for prevention of cardiovascular disease are misleading

References

• Ravnskov U, de Lorgeril M, Diamond DM, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert Rev Clin Pharm. 2018;959–970. DOI:10.1080/17512433.2018.1519391
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open. 2016;6:e010401.
   PubMed Web of Science ®Google Scholar
• Park CH, Kang EW, Park JT, et al. Association of serum lipid levels over time with survival in incident peritoneal dialysis patients. J Clin Lipidol. 2017;11:945–954.
   PubMed Web of Science ®Google Scholar
• Zuliani G, Volpato S, Dugo M, et al. Combining LDL-C and HDL-C to predict survival in late life: the InChianti study. PLoS One. 2017;12:e0185307.
   PubMed Web of Science ®Google Scholar
• Tanamas SK, Saulnier PJ, Hanson RL, et al. Serum lipids and mortality in an American Indian population: A longitudinal study. J Diabetes Complic. 2018;32:18–26.
   PubMed Web of Science ®Google Scholar
• Harari G, Green MS, Magid A, et al. Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up. Am J Cardiol. 2017;119:1193–1198.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wu Y, Yu S, et al. Low-density lipoprotein cholesterol and all-cause mortality: findings from the China health and retirement longitudinal study. BMJ Open. 2020;10:e036976.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Mizuno A, Shimbo T, et al. The association of repeatedly measured low-density lipoprotein cholesterol and all-cause mortality: a longitudinal study. Internat J Cardiol. 2020. DOI:10.1016/j.ijcard.2020.03.011
   Web of Science ®Google Scholar
• Orozco-Beltran D, Gil-Guillen VF, Redon J. Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: the ESCARVAL-RISK study. PLoS One. 2017;12:e0186196.
   PubMed Web of Science ®Google Scholar
• Bendzala M, Sabaka P, Caprnda M, et al. Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women: A 10-year follow-up. Wien Klin Wochenschr. 2017;129:793–798.
   PubMed Web of Science ®Google Scholar
• Charlton J, Ravindrarajah R, Hamada S, et al. Trajectory of total cholesterol in the last years of life over age 80 years: cohort study of 99,758 participants. J Gerontol A Biol Sci Med Sci. 2018;73:1083–1089.
   PubMed Web of Science ®Google Scholar
• Dimsdale JE, Herd A. Variability of plasma lipids in response to emotional arousal. Psychosom Med. 1982;44:413–430.
   PubMed Web of Science ®Google Scholar
• Frideman M, Rosenman RH, Carroll V. Changes in the serum cholesterol and blood clotting time in men subjected to cyclic variation of occupational stress. Circulation. 1958;17:852–861.
   PubMed Web of Science ®Google Scholar
• Esler M. Mental stress and human cardiovascular disease. Neurosci Biobehav Rev. 2017;74:269–276.
   PubMed Web of Science ®Google Scholar
• Hammadah M, Kim JH, Al Mheid I, et al. Coronary and peripheral vasomotor responses to mental stress. J Am Heart Assoc. 2018;7:pii: e008532.
   Web of Science ®Google Scholar
• Burgess S, Timpson NJ, Ebrahim S, et al. Mendelian randomization: where are we now and where are we going? Int J Epidemiol. 2015;44:379–388.
   PubMed Web of Science ®Google Scholar
• Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156:438–444.
   PubMed Web of Science ®Google Scholar
• Mortensen MB, Falk E, Li D, et al. Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA. JACC Cardiovasc Imaging. 2018;11:221–230.
   PubMed Web of Science ®Google Scholar
• Hecht HS, Superko HR. Electron beam tomography and national cholesterol education program guidelines in asymptomatic women. J Am Coll Cardiol. 2001;37:1506–1511.
   PubMed Web of Science ®Google Scholar
• Henein M, Granåsen G, Wiklund U, et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 2015;184:581–586.
   PubMed Web of Science ®Google Scholar
• Nakazato R, Gransar H, Berman DS, et al. Statins use and coronary artery plaque composition: results from the International Multicenter CONFIRM Registry. Atherosclerosis. 2012;225:148–153.
   PubMed Web of Science ®Google Scholar
• Hero C, Svensson AM, Gidlund P, et al. LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes. Diabet Med. 2016;33:316–323.
   PubMed Web of Science ®Google Scholar
• Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421–1430.
   PubMed Web of Science ®Google Scholar
• Roselli Della Rovere G, Lapolla A, Sartore G, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13:46–51.
   PubMed Web of Science ®Google Scholar
• de Lorgeril M, Hamazaki T, Kostucki W, et al. Is the use of cholesterol-lowering drugs for the prevention of cardiovascular complications in type 2 diabetics evidence-based? A systematic review. Rev Recent Clin Trials. 2012;7:150–157.
   PubMedGoogle Scholar
• Klimentidis YC, Arora A, Newell M, et al. Phenotypic and genetic characterization of lower LDL cholesterol and increased type 2 diabetes risk in the UK Biobank. Diabetes. 2020;69:2194–2205.
   PubMed Web of Science ®Google Scholar
• Ravnskov U, de Lorgeril M, Kendrick M, et al. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Med Hypotheses. 2018;121:60–63.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38:2459–2472.
   PubMed Web of Science ®Google Scholar
• Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in get with the guidelines. Am Heart J. 2009;157:111–117.
   PubMed Web of Science ®Google Scholar
• Al-Mallah MH, Hatahet H, Cavalcante JL, et al. Low admission LDL- cholesterol is associated with increased 3-year all-cause mortality in patients with non-ST segment elevation myocardial infarction. Cardiol J. 2009;16:227–233.
   PubMed Web of Science ®Google Scholar
• Rabaeus M, de Lorgeril M. A systematic review of clinical trials testing CETP and PCSK9 inhibitors: the cholesterol-heart theory—time for a requiem? J Controvers Biomed. 2019;5:4–11.
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. N Engl J Med. 1996;335:1001–1009.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630.
   PubMed Web of Science ®Google Scholar
• Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2003;59:1343–1356.
   Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Matsuzaki M, Kita T, Mabuchi H, et al. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J. 2002;66:1087–1095.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–589.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52:255–262.
   PubMed Web of Science ®Google Scholar
• Diamond DM, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Exp Rev Clin Pharmacol. 2015;8:201–210.
   PubMed Web of Science ®Google Scholar
• Sultan S, Hynes N. The ugly side of statins. Systemic appraisal of the contemporary unknown unknowns. Open J Endocr Metab Dis. 2013;3:179–185.
   Google Scholar
• Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58:1109–1117.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.
   PubMed Web of Science ®Google Scholar
• Padala KP, Padala PR, McNeilly DP, et al. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother. 2012;10:296–302.
   PubMedGoogle Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci. 2015;11:1–23.
   PubMed Web of Science ®Google Scholar
• Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Exp Rev Clin Pharmacol. 2015;8:189–199. Erratum in: Exp Rev Clin Pharmacol 2015;8:503-5.
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen JO, Langsjoen AM, et al. Statin-associated cardiomyopathy responds to statin withdrawal and administration of coenzyme Q10. Perm J. 2019;23(18):257.
   Google Scholar
• Diamond DM, de Lorgeril M, Kendrick M, et al. Formal comment on “Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease”. PLoS One. 2019;14:e0205138. eCollection 2019.
   PubMed Web of Science ®Google Scholar
• Montesanto A, Pellegrino D, Geracitano S, et al. Cardiovascular risk profiling of long-lived people shows peculiar associations with mortality compared with younger individuals. Geriatr Gerontol Int. 2019;19:165–170.
   PubMed Web of Science ®Google Scholar
• Penson PE, Long DL, Howard G, et al. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study. Cardiovasc Res. 2019;115:204–212.
   PubMed Web of Science ®Google Scholar
• Berton G, Cordiano K, Mahmoud HT, et al. Plasma lipid levels during ASC: association with 20 year mortality: the ABC-5 study on heart disease. Eur J Prev Cardiol. 2019. DOI:10.1177/2047487319873061
   PubMedGoogle Scholar
• Degano IR, Ramos R, Garcia-Gil M. Three-year events and mortality in cardiovascular disease patients without lipid-lowering treatment. Eur J Prev Cardiol. 2019. DOI:10.1177/2047487319862103
   PubMedGoogle Scholar
• Maihofer AX, Shadyab AH, Wild RA, et al. Associations between serum levels of cholesterol and survival to age 90 in postmenopausal women. J Am Geriatr Soc. 2020;68:288–296.
   PubMed Web of Science ®Google Scholar
• Sittiwet C, Simonen P, Gylling H, et al. Mortality and cholesterol metabolism in subjects aged 75 years and older: the Helsinki businessmen study. J Am Geriatr Soc. 2020;68:281–287.
   PubMed Web of Science ®Google Scholar